Protein-protein interaction network could reveal the relationship between the breast and colon cancer

Gastroenterology and Hepatology from Bed to Bench

Volumn 8, Issue 3, 2015, Pages 215-224

  Zamanian Azodi, Mona ^a   Rezaei Tavirani, Mostafa ^a   Rahmati Rad, Sara ^b   Hasanzadeh, Hadi ^c   Tavirani, Majid Rezaei ^d   Seyyedi, Samaneh Sadat ^e  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Colon cancer; Gene ontology; Protein protein interaction network

Indexed keywords

BIOLOGICAL MARKER; MYC PROTEIN; ONCOPROTEIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN JUN; PROTEIN P53; RAC PROTEIN; RAF PROTEIN; RHO FACTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; T CELL FACTOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ANAPHASE; APOPTOSIS; ARTICLE; BAD GENE; BAX GENE; BCL2 GENE; BREAST CANCER; CASP3 GENE; CASP9 GENE; COLON CANCER; CYCLIND1 GENE; DISEASE ASSOCIATION; FEMALE; GENE; GENE IDENTIFICATION; GENETIC DATABASE; GENETIC SCREENING; HUMAN; JUN GENE; LEF GENE; MALE; METAPHASE; MITOCHONDRIAL PERMEABILITY; ONCOGENE K RAS; ONCOGENE MYC; P13K GENE; PROTEIN PROTEIN INTERACTION; RAF GENE; REGULATORY MECHANISM; RHO GENE; SIGNAL TRANSDUCTION; SMAD2 GENE; SMAD3 GENE; SMAD4 GENE; TCF GENE; TGFR1 GENE; TGFR2 GENE; TP53 GENE; TUMOR SUPPRESSOR GENE;

EID: 84938680009     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Rezaie-Tavirani M, Fayazfar S, Heydari-Keshel S, Rezaee MB, Zamanian-Azodi M, Rezaei-Tavirani M, et al. Effect of essential oil of Rosa Damascena on human colon cancer cell line SW742. Gastroenterol Hepatol Bed Bench 2013;6:25-31.
2. Zamanian-Azodi M, Rezaei-Tavirani M, Hasanzadeh H, Rahmati Rad S, Dalilan S. Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach. Gastroenterol Hepatol Bed Bench 2015;8:6-18.
3. Rezaei-Tavirani M, Safaei A, Zali MR. The Association between Polymorphismsin Insulin and Obesity Related Genesand Risk of Colorectal Cancer. Iranian J Cancer Prev 2013;6:179-85.
4. Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. Biomed Res Int 2011;2011:1-19.
5. Rezaei-Tavirani M, Zamanian-Azodi M, Azizi-Jalilian F, Khodakarim S. Biomarker Profiling (Erbb2, P53, and PR) for Stage I of Breast Cancer. Journal of Paramedical Sciences 2013;4:47-50.
6. Narvaez CJ, Matthews D, LaPorta E, Simmons KM, Beaudin S, Welsh J. The impact of vitamin D in breast cancer: genomics, pathways, metabolism. Front Physiol 2014;5:213.
7. Zamanian Azodi M, Ardestani H, Dolat E, Mousavi M, Fayazfar S, Shadloo A. Breast cancer: Genetics, risk factors, molecular pathology and treatment. Journal of Paramedical Sciences 2013;4:112-17.
8. Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, et al. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res 2014;34:1071-7.
9. Dworkin AM, Huang THM, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Sem Cancer Biol 2009;19:165-71.
10. Hinck L, Näthke I. Changes in cell and tissue organization in cancer of the breast and colon. Curr Opin Cell Biol 2014;26:87-95.
11. Gulcelik MA, Colakoglu K, Dincer H, Dogan L, Yenidogan E, Gulcelik NE. Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev 2012;13:395-8.
12. Sung MK, Yeon JY, Park SY, Park JHY, Choi MS. Obesity-induced metabolic stresses in breast and colon cancer. Ann N Y Acad Sci 2011;1229:61-68.
13. Gorham ED, Garland CF, Garland FC. Acid haze air pollution and breast and colon cancer mortality in 20 Canadian cities. Cana J Public Health 1988;80:96-100.
14. Batty D, Thune I. Does physical activity prevent cancer? Evidence suggests protection against colon cancer and probably breast cancer. BMJ 2000;321:1424-25.
15. Klampfer L. Vitamin D and colon cancer. World J Gastrointest Oncol 2014;6:430-37.
16. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
17. Lin J, Gan CM, Zhang X, Jones S, Sjöblom T, Wood LD, et al. A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res 2007;17:1304-18.
18. Zali H, Rezaei Tavirani M, Rezaei Tavirani M. Protein-Protein Interaction Network of Alzheimer's disease from Human Hippocampal Proteome. International Journal of Analytical, Pharmaceutical and Biomedical Sciences 2015;4:130-44.
19. Rezaei-Tavirani M. Zali H. Meningioma proteinprotein interaction network. Arch Iran Med 2014;17:262-272.
20. Han J-DJ, Bertin N, Hao T, Goldberg DS, Berriz GF, Zhang LV, et al. Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature 2004;430:88-93.
21. Liu X, Ma Y, Yang W, Wu X, Jiang L, Chen X. Identification of therapeutic targets for breast cancer using biological informatics methods. Mol Med Rep. 2015;12:1789-95.
22. Han L, Wu Z, Zhao Q. Revealing the molecular mechanism of colorectal cancer by establishing LGALS3 related protein-protein interaction network and identifying signaling pathways. Int J Mol Med 2014;33:581-8.
23. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
24. Assenov Y, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics 2008;24:282-4.
25. Rivera CG, Vakil R, Bader JS. NeMo: network module identification in Cytoscape. BMC Bioinformatics 2010;11:61.
26. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009;25:1091-3.
27. Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-protein interaction networks (PPI) and complex diseases. Gasteroenterol Hepatol Bed Bench 2014;7:17-31.
28. Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 2003;4:2.
29. Ekman D, Light S, Björklund ÅK, Elofsson A. What properties characterize the hub proteins of the proteinprotein interaction network of Saccharomyces cerevisiae? Gen biol 2006;7:R45.
30. Kar G, Gursoy A, Keskin O. Human cancer proteinprotein interaction network: a structural perspective. PLoS Comput Biol 2009;5: e1000601.
31. Zamanian-Azodi M, Rezaei-Tavirani M, Mortazavian A, Vafaee R, Rezaei-Tavirani M, Zali H, et al. Application of proteomics in cancer study. American Journal of Cancer Science 2013;2:116-34.
32. Zali H, Ahmadi G, Bakhshandeh R, Rezaei-Tavirani M. Proteomic analysis of gene expression during human esophagus cancer. Journal of Paramedical Sciences 2011;2:37-44.
33. Zali H, Rezaei-Tavirani M, Vafaee R, Rezaei-Tavirani M. Gastric cardia adenocarcinoma pathway analysis. Gastroenterol Hepatol Bed Bench 2013;6:11-18.
34. Han S-U, Kim H-T, Seong DH, Kim Y-S, Park Y-S, Bang Y-J, et al. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 2004;23:1333-41.
35. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453-56.
36. Rodrigues NR, Rowan A, Smith M, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci 1990;87:7555-59.
37. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-56.
38. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 2006;15:718-27.
39. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 1997;57:1569-74.
40. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550-62.
41. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011;10:1093-101.
42. Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev 2013;14:2201-205.
43. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nature Rev Cancer 2009;9:95-107.
44. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002;1:226-31.